Developed from extensive market feedback, we have designed this new closure system to feature several important updates: intuitive handling, innovative functionality, and a premium design that fits a wide range of syringe formats. Together, these advances will further enhance the protection and usability that V‑OVS® next offers for applications across a broad range of markets such as ophthalmology, aesthetic injectables, diluents, and biologics. Unveiled at PharmaPack 2025 and met with significant industry interest, the closure has since progressed through multiple key steps toward commercial readiness in 2027.
After a robust, multi‑cycle development process, we have finalized the design of V‑OVS® next and initiated industrialization. As part of that process, we will provide our primary syringe glass suppliers with NFHU materials for further implementation and testing across a range of syringe formats.
With the first biopharma customers already giving positive feedback, we’re excited to see market uptake by some glass suppliers. We’ve already had successful conversations with multiple value chain partners and received consistently encouraging responses that reinforce our confidence in this launch.
Lars Hahn, Senior Vice President Global Sales Organization
We have completed two more important verification steps of our own: After successfully completing a first Human Factors study earlier in 2025, a second Human Factors study and a key Functional Study have both delivered positive results for V‑OVS® next.
While the earlier evaluation focused on product‑ and user‑related feedback, the second Human Factors study additionally included a use‑related risk analysis to confirm that V‑OVS® next enables safe and effective handling. After evaluating the closure system’s usability and comparing it with the original V‑OVS® closure, study participants confirmed that V‑OVS® next is a user‑friendly design offering an enhanced user experience with a differentiating look and feel.
In addition, we evaluated the structural performance of V‑OVS® next during manufacturing and handling. Initial tests demonstrated that V‑OVS® next further improves upon the performance of the existing V‑OVS®, supports intuitive handling, and reduces the likelihood of misuse.
Our goal was to combine safety, usability, and design in a way that truly benefits the user of the system. The positive results from both usability and performance evaluations confirm that V-OVS® next delivers on these objectives.
Dr. Claus Feußner, Senior Vice President Vetter Development Service
With these milestones achieved, we will continue to advance V‑OVS® next along its pathway toward launch. Industrialization is on track, and commercialization is scheduled for 2027. Post‑launch, we will continue to offer both V‑OVS® and V‑OVS® next, expanding our portfolio of solutions for customers’ syringe‑based products. Furthermore, V‑OVS® and V‑OVS® next share the same contact materials and a range of industry‑standard tip‑cap rubber formulations, making it easy to upgrade to the new system as a lifecycle measure for existing drugs or a differentiating factor for new drugs.
